NDA 217171 · Apellis Pharms
Syfovre
Pegcetacoplan · Intravitreal · Complement Inhibitor
Priority reviewLast checked: Nov 20, 2026Latest source record: Mar 27, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Feb 17, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
12 Phase 3, 6 recruiting
FAERS reports
1,546
1,088 serious, 99 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 16, 2025.
SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). ( 1 )
Mechanism: Pegcetacoplan binds to complement protein C3 and its activation fragment C3b with high affinity thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SYFOVRE · PEGCETACOPLAN 15MG/0.1ML (15MG/0.1ML) · SOLUTION, INTRAVITREAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pegcetacoplan" as an intervention, any sponsor and status, largest first.
- An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDPivotal-lookingCompleted
Apellis Pharmaceuticals, Inc.Industry
NCT04770545 · 792 participants · Start Mar 4, 2021 · Primary completion Sep 5, 2025
Drug: PEGCETACOPLAN (APL-2) · For: Geographic Atrophy Secondary to Age-related Macular Degeneration
Sites: Phoenix, Arizona; Bakersfield, California; Campbell, California · 175 sites in all
- A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationPivotal-lookingCompleted
Apellis Pharmaceuticals, Inc.Industry
NCT03525613 · 637 participants · Start Aug 31, 2018 · Primary completion Jun 28, 2021
Drug: APL-2; APL-2 · For: Geographic Atrophy
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 112 sites in all
- Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular DegenerationPivotal-lookingCompleted
Apellis Pharmaceuticals, Inc.Industry
NCT03525600 · 621 participants · Start Aug 31, 2018 · Primary completion Jun 21, 2021
Drug: APL-2; APL-2 · For: Geographic Atrophy
Sites: Phoenix, Arizona; Arcadia, California; Bakersfield, California · 141 sites in all
- MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingTerminated
Apellis Pharmaceuticals, Inc.Industry
NCT04579666 · 249 participants · Start Sep 30, 2020 · Primary completion Mar 31, 2023
Drug: Pegcetacoplan (APL-2) · For: Amyotrophic Lateral Sclerosis; Motor Neuron Disease
Sites: Los Angeles, California; Aurora, Colorado; Tampa, Florida · 60 sites in all
- Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic AtrophyPivotal-lookingCompleted
Apellis Pharmaceuticals, Inc.Industry
NCT02503332 · 246 participants · Start Sep 24, 2015 · Primary completion Jul 14, 2017
Drug: Pegcetacoplan · For: Geographic Atrophy
Sites: Mobile, Alabama; Phoenix, Arizona; Beverly Hills, California · 46 sites in all
Apellis Pharmaceuticals, Inc.Industry
NCT07215390 · 240 participants (planned) · Start Jun 23, 2025 · Primary completion Jun 25, 2027
Drug: APL-3007, pegcetacoplan (APL-2); APL-3007, pegcetacoplan (APL-2) · For: Geographic Atrophy Secondary to Age-related Macular Degeneration
Sites: Gilbert, Arizona; Mesa, Arizona; Phoenix, Arizona · 78 sites in all
- A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT06722157 · 202 participants · Start Jan 6, 2025 · Primary completion Oct 26, 2026
Drug: BI 771716; Pegcetacoplan and 1 more · For: Macular Degeneration, Age-related; Geographic Atrophy
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 46 sites in all
Swedish Orphan BiovitrumIndustry
NCT07746895 · 150 participants (planned) · Start Aug 5, 2026 · Primary completion Dec 31, 2031
Drug: Pegcetacoplan · For: C3 Glomerulopathy (C3G); Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Sites: Kingswood, Australia; Woolloongabba, Australia; Graz, Austria · 101 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- visual impairment144
- fatigue133
- off label use131
- vitreous floaters115
- haemoglobin decreased94
- haemolysis83
- uveitis79
- vitritis75
- eye inflammation72
- headache67
- neovascular age-related macular degeneration66
- vision blurred66
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 4 |
| 2022 | 32 |
| 2023 | 262 |
| 2024 | 713 |
| 2025 | 313 |
| 2026 | 222 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Syfovre (PEGcetacoplan/PF)
2024 spending
$5.5M
Beneficiaries
463
1,835 claims
Per beneficiary
$11,896
$22,307.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $1,557,241 |
| 2024 | $5,507,640 |
Part B: Syfovre (Pegcetacoplan/PF) · HCPCS J2781
2024 spending
$404M
Beneficiaries
29,338
148,576 claims
Per beneficiary
$13,766
2024 ASP limit $149.45 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $76,651,580 |
| 2024 | $403,855,395 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.
Fakhouri F, Bomback AS, Ariceta G, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P, Szer J, Weitz I, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS, Grossi FV, El Mehdi D, et al. · Ophthalmology 2020 · Clinical Trial, Phase II, Multicenter Study
- Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia.
Roman E, Fattizzo B, Shum M, et al. · Blood 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
- Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Wong RSM, Navarro-Cabrera JR, Comia NS, et al. · Blood Adv 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: Apellis Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.